Cargando…

EGFR mutations subset in Chinese lung squamous cell carcinoma patients

Research has identified that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) possess large benefits for adenocarcinoma (ADC), although little benefit for squamous cell carcinoma (SCC). The aim of the present study was to investigate the percentage of patients with SCC with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Ying, Yin, Xin, Wen, Miao-Miao, Zhang, Jiao, Wang, Xue-Jiao, Xia, Jing-Hua, Zhang, Yan-Ning, Zhang, Zhi-Pei, Li, Xiao-Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983943/ https://www.ncbi.nlm.nih.gov/pubmed/29620244 http://dx.doi.org/10.3892/mmr.2018.8859

Ejemplares similares

EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
por: Jin, Rui, et al.
Publicado: (2021)

Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response
por: Li, Zhe-Zhen, et al.
Publicado: (2016)

Association between squamous cell carcinoma antigen level and EGFR mutation status in Chinese lung adenocarcinoma patients
por: Zhang, Shuying, et al.
Publicado: (2022)

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment
por: Xie, Xiao-Hong, et al.
Publicado: (2020)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma
por: Memon, Aadil Ahmed, et al.
Publicado: (2017)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
por: Hakozaki, Taiki, et al.
Publicado: (2020)

Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART
por: Jiao, Yanmei, et al.
Publicado: (2011)

Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma
por: Luo, Jia-Wei, et al.
Publicado: (2021)

Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
por: Lv, Yang, et al.
Publicado: (2016)

Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations
por: Gao, Xuejuan, et al.
Publicado: (2019)

Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma
por: Cui, Yong, et al.
Publicado: (2013)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
por: Lu, Yan, et al.
Publicado: (2021)

Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
por: Rao, Ding-Yu, et al.
Publicado: (2023)

Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
por: Peng, Liang, et al.
Publicado: (2014)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
por: Zhong, Hua, et al.
Publicado: (2023)

Clinicopathological Characteristics And EGFR-TKIs Efficacies In Lung Squamous Cell Carcinoma Patients Harboring An EGFR Sensitizing Mutation
por: Zhou, Shaozhang, et al.
Publicado: (2019)

Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients
por: Tian, Hong‐xia, et al.
Publicado: (2022)

SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling
por: Barzegar, Mansoureh, et al.
Publicado: (2017)

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY
por: Nishio, Makoto, et al.
Publicado: (2020)

Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma
por: Peng, MuYun, et al.
Publicado: (2020)

Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer
por: Wen, Miaomiao, et al.
Publicado: (2016)

Correlation between high-resolution computed tomography lung nodule characteristics and EGFR mutation in lung adenocarcinomas
por: Nie, Yunqiang, et al.
Publicado: (2019)

The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis
por: Li, Wen-Ya, et al.
Publicado: (2019)

The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies
por: Ho, Hsiang-Ling, et al.
Publicado: (2019)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
por: Bai, Yongkang, et al.
Publicado: (2023)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients
por: Feng, Wei-neng, et al.
Publicado: (2018)

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
por: Zang, Shu-Zhi, et al.
Publicado: (2017)

The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells
por: Han, Yaguang, et al.
Publicado: (2022)

The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment
por: Hung, Hsiu-Ying, et al.
Publicado: (2016)

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
por: Shi, Yuankai, et al.
Publicado: (2015)

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations
por: Wang, Jia-li, et al.
Publicado: (2022)

Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma
por: Zhou, Xiuzhi, et al.
Publicado: (2018)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma
por: Pan, Deng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1fqundbipf879kkcf78p1f1vqf